All In Biotech

Drug Trial Radar · NCT02556736

AGN-151597 (Formerly RST-001) Phase I/II Trial for Advanced Retinitis Pigmentosa

Phase I/IIa, Open-Label, Dose-Escalation Study of Safety and Tolerability of Intravitreal RST-001 in Patients With Advanced Retinitis Pigmentosa (RP)

Last checked: Nov 20, 2026Latest source record: Jan 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

14

Actual

Start

Dec 14, 2015

Primary completion

Jun 1, 2020

Study completion Oct 21, 2024

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
First posted
Sep 22, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

All participants in phase 1 and phase 2a had hand motion visual acuity or worse. If efficacy was demonstrated from phase 1, better vision subjects could be enrolled; however, efficacy was not demonstrated.

Conditions

  • Advanced Retinitis Pigmentosa

Interventions

  • AGN-151597Drug

    AGN-151597 is a gene therapeutic delivered by intravitreal injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Any Grade 3 or Greater Adverse Event (AE) Considered Related to AGN-151597Time frame: Baseline (Day 1) to 6 Months
  2. Visual Acuity in the Study Eye at Baseline and Month 6Time frame: Baseline (Day 1), 6 Months
  3. Change From Baseline at Month 6 in Full Field Sensitivity in the Study Eye - Blue Light ThresholdTime frame: Baseline (Day 1) to Month 6
  4. Change From Baseline at Month 6 in Full Field Sensitivity in the Study Eye - Red Light ThresholdTime frame: Baseline (Day 1) to Month 6
  5. Change From Baseline at Month 6 in Full Field Sensitivity in the Study Eye - White Light ThresholdTime frame: Baseline (Day 1) to Month 6
  6. Change From Baseline at Month 6 in Ambulation in the Study Eye (Time)Time frame: Baseline (Day 1) to Month 6
  7. Change From Baseline at Month 6 in Ambulation in the Study Eye (Distance)Time frame: Baseline (Day 1) to Month 6
  8. Intraocular Pressure (IOP) Measurements in the Study EyeTime frame: Baseline (Day 1), 6 Months
  9. Anatomical Parameters as Measured in the Study Eye by Color Fundus Photography and AutofluorescenceTime frame: Baseline (Day 1), 6 Months
  10. Change From Baseline at Month 6 in the Anatomical Parameters in the Study Eye as Measured by Spectral Domain-Optical Coherence Tomography (SD-OCT) - Total Retinal Nerve Fibre Layer VolumeTime frame: Baseline (Day 1) to Month 6
  11. Change From Baseline at Month 6 in the Anatomical Parameters in the Study Eye as Measured by Spectral Domain-Optical Coherence Tomography (SD-OCT) - Total Ganglion Cell and Inner Plexiform Layer VolumeTime frame: Baseline (Day 1) to Month 6
  12. Change From Baseline at Month 6 in the Anatomical Parameters in the Study Eye as Measured by Spectral Domain-Optical Coherence Tomography (SD-OCT) - Total Retinal VolumeTime frame: Baseline (Day 1) to Month 6
  13. Change From Baseline at Month 6 in the Anatomical Parameters in the Study Eye as Measured by Spectral Domain-Optical Coherence Tomography (SD-OCT) - Total Retinal ThicknessTime frame: Baseline (Day 1) to Month 6

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • University of California San Francisco - Mission Bay /ID# 235717

    San Francisco, California

  • Cincinnati Eye Institute- Edgewood /ID# 236713

    Edgewood, Kentucky

  • Duke Eye Center /ID# 235715

    Durham, North Carolina

  • Retina Foundation of the Southwest /ID# 235199

    Dallas, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.